B. Charlton

1.1k total citations
47 papers, 757 citations indexed

About

B. Charlton is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Genetics. According to data from OpenAlex, B. Charlton has authored 47 papers receiving a total of 757 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 13 papers in Surgery and 9 papers in Genetics. Recurrent topics in B. Charlton's work include Cystic Fibrosis Research Advances (14 papers), Diabetes and associated disorders (9 papers) and Inhalation and Respiratory Drug Delivery (8 papers). B. Charlton is often cited by papers focused on Cystic Fibrosis Research Advances (14 papers), Diabetes and associated disorders (9 papers) and Inhalation and Respiratory Drug Delivery (8 papers). B. Charlton collaborates with scholars based in Australia, United States and United Kingdom. B. Charlton's co-authors include Hugh Auchincloss, C. Garrison Fathman, Abraham Verghese, Robyn M. Slattery, Jerome P. Kassirer, John P. A. Ioannidis, Meghan Ramsey, Klaus Schindhelm, Diana Bilton and T E Mandel and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Circulation and PLoS ONE.

In The Last Decade

B. Charlton

45 papers receiving 726 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
B. Charlton Australia	13	206	189	169	159	75	47	757
Stephen J. McGeady United States	17	218 1.1×	216 1.1×	99 0.6×	70 0.4×	52 0.7×	64	907
Benjamin Jacobs United Kingdom	15	112 0.5×	52 0.3×	78 0.5×	39 0.2×	102 1.4×	41	668
Catherine M. Biggs Canada	16	61 0.3×	361 1.9×	81 0.5×	111 0.7×	107 1.4×	39	896
Maria Teresa Terreri Brazil	20	163 0.8×	240 1.3×	181 1.1×	96 0.6×	140 1.9×	109	1.2k
Sara Manrique‐Arija Spain	17	206 1.0×	110 0.6×	56 0.3×	69 0.4×	179 2.4×	92	989
Anja Sander Germany	17	103 0.5×	75 0.4×	244 1.4×	58 0.4×	102 1.4×	54	928
David Game United Kingdom	18	103 0.5×	539 2.9×	150 0.9×	47 0.3×	90 1.2×	40	1.1k
Robert W. Ike United States	17	121 0.6×	26 0.1×	328 1.9×	43 0.3×	33 0.4×	46	994
Patricia R. Chess United States	22	859 4.2×	210 1.1×	453 2.7×	34 0.2×	272 3.6×	52	1.5k
Natalia Mena‐Vázquez Spain	17	243 1.2×	85 0.4×	40 0.2×	60 0.4×	154 2.1×	88	1.0k

Countries citing papers authored by B. Charlton

Since Specialization

Citations

This map shows the geographic impact of B. Charlton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Charlton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Charlton more than expected).

Fields of papers citing papers by B. Charlton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. Charlton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Charlton. The network helps show where B. Charlton may publish in the future.

Co-authorship network of co-authors of B. Charlton

This figure shows the co-authorship network connecting the top 25 collaborators of B. Charlton. A scholar is included among the top collaborators of B. Charlton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B. Charlton. B. Charlton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Alrubayyi, Aljawharah, Ester Gea‐Mallorquí, Emma Touizer, et al.. (2021). Characterization of SARS-CoV-2-specific responses in people living with HIV. 29(1). 89–89.

Charlton, B., et al.. (2018). Length of hospitalization and mortality for bleeding during treatment with warfarin, dabigatran, or rivaroxaban. PLoS ONE. 13(3). e0193912–e0193912. 11 indexed citations

Boeck, K. De, Eric G. Haarman, James H. Hull, et al.. (2017). Inhaled dry powder mannitol in children with cystic fibrosis: A randomised efficacy and safety trial. Journal of Cystic Fibrosis. 16(3). 380–387. 27 indexed citations

Verghese, Abraham, B. Charlton, Jerome P. Kassirer, Meghan Ramsey, & John P. A. Ioannidis. (2015). Inadequacies of Physical Examination as a Cause of Medical Errors and Adverse Events: A Collection of Vignettes. The American Journal of Medicine. 128(12). 1322–1324.e3. 128 indexed citations

Bilton, Diana, Moira L. Aitken, K. De Boeck, H. Fox, & B. Charlton. (2012). WS5.2 Inhaled dry powder mannitol in cystic fibrosis (CF): impact on pulmonary exacerbations (PEs) in the Phase III studies (CF-301 & CF-302). Journal of Cystic Fibrosis. 11. S11–S11. 2 indexed citations

Aitken, Moira L., et al.. (2011). 76 Mannitol inhaler device culture: no evidence of an increased microbiological contamination. Journal of Cystic Fibrosis. 10. S20–S20. 1 indexed citations

Bilton, Diana, Moira L. Aitken, Patrick A. Flume, et al.. (2011). 78 Combined data from two phase III studies of Bronchitol (inhaled dry powder mannitol) in adult cystic fibrosis (CF) patients. Journal of Cystic Fibrosis. 10. S20–S20. 2 indexed citations

Bilton, Diana, Philip Robinson, Peter Cooper, et al.. (2011). Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. European Respiratory Journal. 38(5). 1071–1080. 118 indexed citations

Bilton, Diana, Philip Robinson, Patricia Cooper, et al.. (2010). Phase III study of inhaled dry powder mannitol (Bronchitol™) in cystic fibrosis – results from the 6 and 12 month open label phase. Journal of Cystic Fibrosis. 9. S21–S21. 4 indexed citations

10.

Charlton, B. & Abraham Verghese. (2009). Caring for Ivan Ilyich. Journal of General Internal Medicine. 25(1). 93–95. 7 indexed citations

11.

Charlton, B. & Amy Anne D. Lassig. (2006). 46 Inhaled dry powder mannitol (Bronchitol) improves FEV1 in Cystic Fibrosis. Journal of Cystic Fibrosis. 5. S11–S11. 8 indexed citations

12.

Silva, Diego G., B. Charlton, William B. Cowden, & Nikolai Petrovsky. (2003). Prevention of Autoimmune Diabetes through Immunostimulation with Q Fever Complement‐Fixing Antigen. Annals of the New York Academy of Sciences. 1005(1). 423–430. 5 indexed citations

13.

Petrovsky, Nikolai, Diego G. Silva, Luis Socha, Robyn M. Slattery, & B. Charlton. (2002). The Role of Fas Ligand in Beta Cell Destruction in Autoimmune Diabetes of NOD Mice. Annals of the New York Academy of Sciences. 958(1). 204–208. 37 indexed citations

14.

Charlton, B., Hugh Auchincloss, & C. Garrison Fathman. (1994). Mechanisms of Transplantation Tolerance. Annual Review of Immunology. 12(1). 707–734. 110 indexed citations

15.

Loudovaris, Thomas, et al.. (1992). Destruction of xenografts but not allografts within cell impermeable membranes.. PubMed. 24(5). 2291–2. 16 indexed citations

16.

Charlton, B., Robyn H. Guymer, Robyn M. Slattery, & T E Mandel. (1991). Intercellular adhesion molecule (ICAM‐1) inhibition can induce tolerance in vivo. Immunology and Cell Biology. 69(2). 89–93. 7 indexed citations

17.

Charlton, B., et al.. (1988). A comparison of the effects of plasma exchange and immunoadsorption on anti-insulin antibody synthesis in rabbits.. PubMed. 72(2). 326–9. 7 indexed citations

18.

Charlton, B., Klaus Schindhelm, L. C. Smeby, & Peter C. Farrell. (1985). Analysis of immunoglobulin G kinetics in the non-steady state.. PubMed. 105(3). 312–20. 21 indexed citations

19.

Canaud, Bernard, B. Charlton, Jayne Antony, Klaus Schindhelm, & John Moran. (1985). Vascular access for extracorporeal therapy in the rabbit. Laboratory Animals. 19(2). 89–91. 4 indexed citations

20.

Woodhouse, K. W., et al.. (1983). Acute Dapsone Poisoning: Clinical Features and Pharmacokinetic Studies. Human Toxicology. 2(3). 507–510. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact